Results 191 to 200 of about 1,228,020 (262)

Perceptions of Pharmacology Teaching Approaches in Pre‐Doctoral Dental Education

open access: yes
Journal of Dental Education, EarlyView.
Scott D. Papineau   +2 more
wiley   +1 more source

Pediatric vascular compression of the esophagus: Endoluminal functional lumen imaging probe as a complement to imaging and endoscopy

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Vascular anomalies can cause extrinsic esophageal compression, leading to dysphagia or feeding difficulties in children. Diagnosis typically relies on imaging and endoscopy, which may under‐ or overestimate functional narrowing. Endoluminal functional lumen imaging probe (EndoFLIP) provides luminal parameters in real‐time, but its ...
Brett J. Hoskins   +2 more
wiley   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson   +12 more
wiley   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won   +11 more
wiley   +1 more source

A novel knee implant for total knee arthroplasty meets expectations at 10 years. First long‐term follow‐up report of clinical outcomes and survivorship

open access: yesKnee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose Achieving a “forgotten knee” after total knee arthroplasty (TKA) remains a primary goal in modern knee replacement surgery. Anatomic implant designs aim to replicate native knee anatomy and kinematics, potentially improving patient satisfaction and functional outcomes.
Alice Montagna   +6 more
wiley   +1 more source

Impact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes

open access: yesThe Laryngoscope, EarlyView.
ABSTRACT Objective The effectiveness of hypoglossal nerve stimulation (HGNS) for residual obstructive sleep apnea (OSA) in patients with prior bariatric surgery (BS) has not been previously reported. We evaluate and compare HGNS outcomes in this unique population.
Praneet C. Kaki   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy